Pro and anti-oxidants in cardiomyopathy

International Journal of Human Genetics

Volumn 9, Issue 3-4, 2009, Pages 263-267

  Satyanarayana, Matsa Lova ^a   Advithi, Rangaraju ^a   Venkateshwari, Ananthapur ^b   Nallari, Pratibha ^a  

^a OSMANIA UNIVERSITY   (India)

^b OSMANIA UNIVERSITY   (India)

Author keywords

Ceruloplasmin; Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Malondialdehyde; Nitric oxide

Indexed keywords

ANTIOXIDANT; CERULOPLASMIN; EDETIC ACID; FREE RADICAL; MALONALDEHYDE; NITRIC OXIDE; OXIDIZING AGENT;

ARTICLE; BLOOD SAMPLING; CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; HEART FAILURE; HEART MUSCLE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PROGNOSIS; QUANTITATIVE ANALYSIS;

EID: 76049126655     PISSN: 09723757     EISSN: None     Source Type: Journal    
DOI: 10.1080/09723757.2009.11886077     Document Type: Article

References (23)

1. Benamira M, Johnson K, Chaudhary A, Bruner K, Tibbetts C et al 1995. Induction of mutations by replication of malondialdehyde-modified M13 DNA in Escherichia coli: determination of the extent of DNA modification, genetic requirements for mutagenesis, and types of mutations induced. Carcinogenesis (Lon.), 16: 93-99.
2. Bir LS, Suleyman D, Simin R, Mehmet K 2006. Increased Malanoldialdehyde levels in Chronic stage of Ischemic stroke. Tohoku J Exp Med, 208(1): 33-39.
3. Dahle LK, Hill EG, Hollman RT 1962. The thiobarbituric acid reaction and auto oxidation of poly unsaturated fatty acid methyl esters. Arch. Biochem. Biophys, 98: 256-261.
4. Diaz-Velez CR, Garcia-Castineriras S, Mendoza-Ramosa E, Hernandez-Lopez E 1995. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J, 131: 146-152.
5. di Patti MC, Persichini T, Mazzone V, Polticelli F, Colasanti M. et al 2004. Interleukin- 1beta up-regulates iron efflux in rat C6 glioma cells through modulation of ceruloplasmin and ferropotin-1 synthesis. Neurosci Lett, 363(2): 182-186.
6. Fox PL, Mukhopadhyay C, Ehrenwald E 1995. Structure, oxidant activity, and cardiovascular mechanisms of human ceruloplasmin. Life Sci, 56: 1749-1758.
7. Freeman BA, Crapo JD 1982. Biology of disease: free radicals and tissue injury. Lab Invest, 47(5): 412-426.
8. Goishvili N, Kakauridze N, Sanikidze T 2005. The role of oxidative metabolism disturbance in the development of NO-related endothelial dysfunction during chronic hearth failure. Georgian Med News, 122:65-68.
9. Goineau S, Pape D, Guillo P, Ramee MP, Bellissant E 2001. Increased sensitivity of vascular smooth muscle to nitric oxide in dilated cardiomyopathy of Syrian hamsters (Bio TO-2 strain). J Cardiovasc Pharmacol, 37(3): 290-300.
10. 15N nitrate in biological fluids. Annal Biohem, 126: 131-138.
11. rd Edition. Oxford: Oxford University Press.
12. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D et al 2006. American Heart Association Council on Clinical Cardiology, Heart Failure and Transplantation, Council on Clinical Cardiology, Heart Failure and Transplantation Committee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, and Council on Epidemiology and Prevention. Contemporary definitions and classifications of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 113: 1807-1816.
13. Mateescu MA, Chahine R, Roger S, Atanasiu R, Yamaguchi N et al 1995. Protection of myocardial tissue against deleterious effects of oxygen free radicals by ceruloplasmin. Arzneimittel-Forsch Drug Res, 45: 476-480.
14. Naito Y, Takagi T, Uchiyama K, Handa O, Tomatsuri N et al 2002. Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats. Redox Rep, 7: 294-299.
15. Packer L, Glazer AN 1986. Oxygen radicals in biological systems. Meth Enzymol, 186: 113-128.
16. Rakhit RD, Marber MS 2001. Nitric oxide : an emerging role in cardioprotection? Heart, 86: 368-372.
17. Ravin N.A 1961. An improved calorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med, 58: 161-162.
18. Reunanen A, Knekt P, Aaran RK 1992. Serum ceruloplasmin level and the risk of myocardial infarction and stroke. Am J Epidemiol, 136(9): 1082-1090.
19. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B et al 1996. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation, 93: 841-842.
20. Reena TR, Annapurna SD, Ushasree B, Pratibha N, Narasimhan C et al 2004. Pro-Oxidant Malondialdehyde and anti-oxidant ceruloplasmin levels in hypertrophic cardiomyopathy. Indian Heart J, 56: 72-73.
21. Warren JB, Pons F, Brady AJB 1994. Nitric oxide biology: implications for cardiovascular therapeutics. Cardiovasc Res, 28: 25-30.
22. Yamashoji S, Kajimoto G 1983. Antioxidant effect of caeruloplasmin on microsomal lipid peroxidation. FEBS Lett, 152(2): 168-170.
23. Yucel D, Aydogdu S, Cehreli S, Saydam G, Canatan H et al 1998. Increased oxidative stress in dilated cardiomyopathic heart failure. Clin Chem, 44: 148-154.